Cited 0 times in
Treatment outcomes of sunitinib treatment in advanced renal cell carcinoma patients: a single cancer center experience in Korea
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 신상준 | - |
dc.contributor.author | 안정련 | - |
dc.contributor.author | 안중배 | - |
dc.contributor.author | 전홍재 | - |
dc.contributor.author | 정현철 | - |
dc.contributor.author | 홍민희 | - |
dc.contributor.author | 김찬 | - |
dc.contributor.author | 김효송 | - |
dc.contributor.author | 라선영 | - |
dc.date.accessioned | 2015-04-24T17:09:04Z | - |
dc.date.available | 2015-04-24T17:09:04Z | - |
dc.date.issued | 2009 | - |
dc.identifier.issn | 1598-2998 | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/104855 | - |
dc.description.abstract | PURPOSE: The retrospective study was performed to assess the efficacy and toxicity profiles of sunitinib in Korean patients with metastatic renal cell carcinoma (RCC). MATERIALS AND METHODS: Between January 2005 and December 2008, 76 Korean patients with recurrent/metastatic RCC who received sunitinib were retrospectively reviewed. The primary end point was progression-free survival and the secondary end points were overall survival and response rate. We also assessed the toxicities associated with sunitinib treatment. RESULTS: Of the 76 patients, 69 (90.1%) were diagnosed with clear cell RCC. The median progression-free survival and overall survival were 7.2 and 22.8 months, respectively in overall patients. Sixty-two patients (81.6%) received 50 mg 4 week and 2 week off schedule, and 14 patients (18.4%) received 37.5 mg daily on a daily continuous schedule. The objective response rate and disease control rate were 27.6% and 84.2%, respectively. A dose reduction or reduction in dose due to adverse events occurred in 76% of the patients, whereas 11% of the patients had discontinued treatment. Other common laboratory abnormalities were increased serum creatinine (75.6%), elevated alanine aminotransferase (71.0%), neutropenia (61.8%), anemia (69.7%), and increased aspartate aminotrasferase (53.3%). Grade 3/4 toxicities occurred as follows: thrombocytopenia (38.2%), fatigue (10.5%), stomatitis (10.5%), and hand-foot syndrome (9.2%). CONCLUSION: Our results indicate that sunitinib treatment is effective and tolerable for ecurrent/metastatic RCC patients in Korea. Further studies with prognostic or biochemical factors are needed to clarify the different toxicity profiles of this study | - |
dc.description.statementOfResponsibility | open | - |
dc.format.extent | 67~72 | - |
dc.relation.isPartOf | CANCER RESEARCH AND TREATMENT | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.rights.uri | https://creativecommons.org/licenses/by-nc-nd/2.0/kr/ | - |
dc.title | Treatment outcomes of sunitinib treatment in advanced renal cell carcinoma patients: a single cancer center experience in Korea | - |
dc.type | Article | - |
dc.contributor.college | College of Medicine (의과대학) | - |
dc.contributor.department | Dept. of Internal Medicine (내과학) | - |
dc.contributor.googleauthor | Min Hee Hong | - |
dc.contributor.googleauthor | Hyo Song Kim | - |
dc.contributor.googleauthor | Chan Kim | - |
dc.contributor.googleauthor | Jung Ryun Ahn | - |
dc.contributor.googleauthor | Hong Jae Chon | - |
dc.contributor.googleauthor | Sang-Joon Shin | - |
dc.contributor.googleauthor | Joong-Bae Ahn | - |
dc.contributor.googleauthor | Hyun Cheol Chung | - |
dc.contributor.googleauthor | Sun Young Rha | - |
dc.identifier.doi | 10.4143/crt.2009.41.2.67 | - |
dc.admin.author | false | - |
dc.admin.mapping | false | - |
dc.contributor.localId | A02105 | - |
dc.contributor.localId | A02256 | - |
dc.contributor.localId | A02262 | - |
dc.contributor.localId | A03565 | - |
dc.contributor.localId | A03773 | - |
dc.contributor.localId | A04393 | - |
dc.contributor.localId | A01034 | - |
dc.contributor.localId | A01202 | - |
dc.contributor.localId | A01316 | - |
dc.relation.journalcode | J00453 | - |
dc.identifier.eissn | 2005-9256 | - |
dc.identifier.pmid | 19707503 | - |
dc.subject.keyword | Efficacy | - |
dc.subject.keyword | Korea | - |
dc.subject.keyword | Renal cell carcinoma | - |
dc.subject.keyword | Sunitinib | - |
dc.subject.keyword | Toxicity | - |
dc.contributor.alternativeName | Shin, Sang Joon | - |
dc.contributor.alternativeName | Ahn, Jung Ryun | - |
dc.contributor.alternativeName | Ahn, Joong Bae | - |
dc.contributor.alternativeName | Chon, Hong Jae | - |
dc.contributor.alternativeName | Chung, Hyun Cheol | - |
dc.contributor.alternativeName | Hong, Min Hee | - |
dc.contributor.alternativeName | Kim, Chan | - |
dc.contributor.alternativeName | Kim, Hyo Song | - |
dc.contributor.alternativeName | Rha, Sun Young | - |
dc.contributor.affiliatedAuthor | Shin, Sang Joon | - |
dc.contributor.affiliatedAuthor | Ahn, Jung Ryun | - |
dc.contributor.affiliatedAuthor | Ahn, Joong Bae | - |
dc.contributor.affiliatedAuthor | Chon, Hong Jae | - |
dc.contributor.affiliatedAuthor | Chung, Hyun Cheol | - |
dc.contributor.affiliatedAuthor | Hong, Min Hee | - |
dc.contributor.affiliatedAuthor | Kim, Chan | - |
dc.contributor.affiliatedAuthor | Kim, Hyo Song | - |
dc.contributor.affiliatedAuthor | Rha, Sun Young | - |
dc.citation.volume | 41 | - |
dc.citation.number | 2 | - |
dc.citation.startPage | 67 | - |
dc.citation.endPage | 72 | - |
dc.identifier.bibliographicCitation | CANCER RESEARCH AND TREATMENT, Vol.41(2) : 67-72, 2009 | - |
dc.identifier.rimsid | 42525 | - |
dc.type.rims | ART | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.